Pharmaceutical composition for treating pulmonary fibrosis and application thereof

A technology of pulmonary fibrosis and composition, which is applied in the field of pharmaceutical composition for the treatment of pulmonary fibrosis, can solve the complex mechanism of pulmonary fibrosis, the inability to effectively improve the prognosis and survival of patients with pulmonary fibrosis, and the lack of breakthrough progress in treatment, etc. problem, to achieve the effect of enhanced synergy and large market development value

Active Publication Date: 2021-04-13
MUDANJIANG MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the results of clinical research on the treatment of pulmonary fibrosis show that whether it is corticosteroids or immunosuppressants and other treatments, its efficacy in the treatment of interstitial lung diseases is poor; the above drug treatments cannot effectively improve the prognosis and survival of patients with pulmonary fibrosis
[0006] Due to the complex mechanism of pulmonary fibrosis and many participating factors, there is still no breakthrough in the treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The effect of embodiment 1 pharmaceutical composition on rat lung fibroblast proliferation

[0022] Primary culture of rat lung fibroblasts: take out Wistar suckling mice 1-4 days after birth, soak the suckling mice in alcohol, take them out, transfer them to a glass petri dish on an ultra-clean table, and sterilize the suckling mice by surgery. Rat lung tissue was removed. Place it in a glass plate filled with PBS (containing 200U / ml penicillin), and wash away the blood. Divide the lung into several lobes with ophthalmic scissors, remove the surrounding blood clots and fibrous tissue with ophthalmic scissors, cut off the bronchi and blood vessels at the hilum with ophthalmic scissors, and rinse once with PBS containing double antibodies. Mince the lung tissue into 1mm 3 size, add PBS containing double antibody, blow open the lung tissue block, let it stand for 15 minutes, and replace it with new PBS. Draw tissue pieces and inoculate them in culture bottles, about 2...

Embodiment 2

[0032] Example 2 Effect of pharmaceutical composition on human alveolar epithelial cell fibrosis model induced by TGF-β1

[0033] For pulmonary fibrosis, part of the proliferation of fibroblasts comes from its self-proliferation, and the other part comes from the conversion of alveolar epithelial cells into fibroblasts under the condition of injury by cytokines. Therefore, on the basis of the test results in Example 1, we further investigated the effect of the pharmaceutical composition on the fibrosis model of human alveolar epithelial cells induced by TGF-β1.

[0034] Test method: Take the human alveolar epithelial cell line (A549) in the logarithmic growth phase, and use 5×10 3cells / ml were inoculated in 96-well cell culture plates, 200ul per well; placed in DMEM medium containing 10% FBS and cultivated for 24h; then added TGF-β1 (model group) with a final concentration of 10ng / ml, and the blank group added no The same amount of medium containing TGF-β1, cultured in the ...

Embodiment 3

[0049] The influence of embodiment 3 pharmaceutical compositions on the rat pulmonary fibrosis model induced by bleomycin

[0050] Test method: Take about 200g Wistar rats and divide them randomly into control group, model group and drug administration group; the rats are fasted for one night and start modeling. All rats are anesthetized by intraperitoneal injection of 10% chloral hydrate. After anesthesia, the rats were fixed on the mouse board in the supine position, the skin of the neck was cut, the neck muscles were bluntly separated, and the trachea was fully exposed. The model group and the drug group were injected with 5 mg / kg Bleomycin into the trachea at one time. To make the medicinal solution evenly distributed in the lungs, a model of pulmonary fibrosis was established, and the control group was injected with the same amount of normal saline. After the rats woke up, intraperitoneal injection was started, once a day, the model group and the control group were inje...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition for treating pulmonary fibrosis, which belongs to the field of medicine. The pharmaceutical composition includes an NMDA receptor antagonist and an angiotensin converting enzyme inhibitor. The weight ratio of the NMDA receptor antagonist to the angiotensin-converting enzyme inhibitor is 1:1-100. The present invention also provides related preparations comprising the pharmaceutical composition and applications thereof.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating pulmonary fibrosis, which belongs to the field of medicine. Background technique [0002] Pulmonary fibrosis (PF) is a severe lung disease, which is the final outcome of the progression of interstitial lung disease (ILD) caused by various etiologies. Many ILD patients with unknown causes are finally diagnosed with connective tissue disease (connective tissue disease, CTD), which is called connective tissue disease-related interstitial lung disease. Among them, systemic sclerosis has the highest incidence rate, which can be as high as 60-70%. Once a patient develops pulmonary fibrosis, the prognosis is extremely poor, and he may die from severe infection and / or respiratory failure in a short period of time. [0003] The exact pathogenesis of pulmonary fibrosis is unclear; however, it is generally believed to be related to inflammation, cytokines, oxidative stress, alveolar epithelial ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K38/05A61K31/13A61K31/704A61P11/00
CPCA61K31/13A61K31/704A61K38/05A61K45/06A61P11/00A61K2300/00
Inventor 刘海英徐颖于得泓曲治权战伟周鑫王书惠赵志轩刘伦翠白吉祥
Owner MUDANJIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap